Document Status
This document has been corrected
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
10.1007/s40261-019-00826-0
Published Online:
2019-07-18
Journal:
Clinical Drug Investigation
Loading...
Authors:
Katherine A. Lyseng-Williamson
NOW
2020-02-10
•
Correction
Loading...
10.1007/s40261-020-00892-9
* information provided by CrossRef
2019-09-12
•
Correction
Loading...
10.1007/s40261-019-00852-y
* information provided by CrossRef
2019-08-17
•
Correction
Loading...
10.1007/s40261-019-00839-9
* information provided by CrossRef
2019-07-18
•
Published
2019-09-12
•
Correction
Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
10.1007/s40261-019-00852-y
* information provided by CrossRef
2019-08-17
•
Correction
Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
10.1007/s40261-019-00839-9
* information provided by CrossRef
2020-02-10
•
Correction
Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
10.1007/s40261-020-00892-9
* information provided by CrossRef
This document has been corrected
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
10.1007/s40261-019-00826-0
Published Online:
2019-07-18
Journal:
Clinical Drug Investigation
•
Publisher:
Springer Science and Business Media LLC
Authors:
Katherine A. Lyseng-Williamson
